NY-CHRISTIE’S
21.12.2019 00:19:24 CET | Business Wire | Press release
Christie’s announced auction channel sales of £3.9 billion (US$5 billion) for 2019.
Key highlights for the year included:
- A new top price for any living artist at auction, achieved with Jeff Koon’s Rabbit, which realized US$91,075,000 at Christie’s New York in May 2019.
- Numerous record prices in 2019 , including top prices for artworks and objects sold in London (David Hockney, Henry Geldzahler and Christopher Scott , for £37,661,248/US$49,521,696), Hong Kong (Sanyu, Five Nudes , for HK$303,984,992/US$38,848,420) and Geneva (Patek Philippe Grandmaster Chime ref. 6300A for ONLY WATCH for CHF31,000,000/US$31,244,094). In Paris Nicolas de Staël’s Parc des Princes realized €20,000,000/US$22,254,368, and set a record for the artist and was the top price for any lot sold at Christie’s Paris this year.
- Christie’s remained the auction house of choice for major private and estate collections, achieving the top three results for named collections in 2019 with Masterpieces from the Collection of S.I. Newhouse, The Robert B. and Beatrice C. Mayer Family Collection, and Maharajas and Mughal Magnificence.
- Strong results were also achieved for the collections of notable collectors David Gilmour, Drue Heinz, the Irving Collection, James and Marilynn Alsdorf, Terry Allen Kramer, Eileen and I.M. Pei, Richard L. Weisman, George Michael, the Clarke Collection, Ron and Diane Disney Miller, the Matthys-Colle Collection, works from the UniCredit Group, Jeremy Lancaster, and masterpieces from a Rothschild Collection.
Guillaume Cerutti, Chief Executive Officer, commented: “Amid a challenging global environment, demand for art remains strong and is reflected in our 2019 results, especially for Modern and Contemporary art. In the last month alone, we were particularly pleased by the results achieved in New York for Christie’s 20th Century Art week, in Hong Kong for our Autumn sale series—despite a heightened political context—and in London during our Classic Week sales, including Old Masters. We are looking forward to continuing the momentum in 2020.”
For more on Christie’s top 2019 moments, please visit our online feature here .
Christie’s will publish full 2019 results, inclusive of private and e-commerce channel sales, in early 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005580/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom